Peptides For Women Event - Peptide Testing 101

From the Peptides for Women Event — August 4, 2026

Disclaimer:

Information provided is for educational purposes only and does not constitute regulatory or medical advice. Testing requirements and applicability depend on the specific formulation, intended use, and current USP/FDA standards. Always consult the official chapters and your quality/regulatory team.

Two Movements, One Bottleneck

On August 4 we gave a short Peptide Testing 101 sponsored talk at the Peptides for Women event in San Francisco organized by Jeff Tang at TIAT.

Sapho Bio Team presenting at the Peptides for Women event

Here are some key points from the talk:

We’re at the intersection point of two huge tidal waves: the women’s health movement and the rapid rise of peptides. Both act as a forcing function to increase awareness and raise the quality bar with respect to testing standards, sterility assurance, and the reliability of what ultimately reaches patients.

There is an actively growing supply of next-generation peptides that have already been investigated for a range of applications. At the same time, there is also clear demand from both women and men. But, we believe that the biggest practical bottleneck between the two is testing.

Testing is the critical bottleneck between peptide supply and demand

Where We Operate

Testing happens at several points in the peptide production process:

• Manufacturers of the active pharmaceutical ingredient (API)

• Compounding pharmacies performing required checks, including visual inspection

• Independent testing laboratories

Based in San Carlos, California, Sapho Bio is a precision measurement company that provides lot-release and stability testing to compounding pharmacies across the United States.

Sapho Bio by the numbers

Faster Lot Release

Our methods are validated to USP standards and focus on the core requirements for lot release: rapid sterility and endotoxin testing. The process begins with a one-time method suitability study tailored to each compounding pharmacy and each specific peptide formula. Once this foundation is established, subsequent lot-release testing moves much faster.

Sterility results are available in 2 business days using our proprietary qPCR-based validated rapid method (USP <1223>), with the traditional 14-day USP <71> option also available. Endotoxin testing (USP <85>) follows the same accelerated timeline. Potency testing is offered as an additional quality-control service for interested clients.

What we’ve heard repeatedly from the industry is that speed is one of the clearest advantages in this market. Product that sits in quarantine is product that isn’t reaching patients. That is why a growing number of compounding pharmacies have chosen Sapho Bio for their testing needs.

Why Stability Matters

Stability testing is equally important. A peptide vial may carry an expiration date, or it may be intended for multiple draws and contain a preservative. Pharmacies increasingly need data that support longer beyond-use dates (BUD) under USP <797> for Category 2 and Category 3 compounded sterile preparations.

Our stability programs are designed to generate the chemical and physical data required for those extended BUDs. They typically include:

• Stability-indicating HPLC methods that separate the API from degradation products

• Custom designs for refrigerated, frozen, or room-temperature storage

• Defined pull points with potency, pH, appearance, and container-closure assessment, plus sterility and endotoxin testing at study endpoints

Ultimately, we produce documentation that pharmacies need to extend BUDs with greater confidence.

Sapho Bio Stability Studies

Our Numbers

As we’ve shared at the event, our testing laboratory has supported:

• More than 20 compounding pharmacy clients

• Over 600 lot-release tests

• Evaluation of more than 30 compounds

The compounds we’ve evaluated include widely discussed peptides such as tirzepatide and semaglutide, along with a broader range of peptides, amino acids, vitamins, cofactors, and small-molecule compounds.

Compounds We Test

Questions Worth Asking

One of the last things we shared during the presentation were the following questions that women could consider asking their physician if they’re curious about taking peptides:

• Does my family medical history make this peptide safe for me?

• Will this interact with my birth control, HRT, or medications?

• How will this affect my menstrual cycle or fertility?

• Can you confirm the product’s testing and regulatory status?

• Do I need to cycle on and off this peptide or take it continuously?

• What hormone panel and blood tests do I need before starting?

Throughout the event, many attendees stopped by and took home printed versions of these questions. Some of these very questions were raised during the panel conversations that followed. These related to key insights shared by Dr. Joelle Osias, a Hopkins- and Stanford-trained gynecologist and founder of an endometriosis, PCOS, and hormone care clinic in Palo Alto who has used peptides clinically, and Lily Niehaus, a pre-med student living with endometriosis who has experienced meaningful benefits from peptide therapy.

Both recently spoke at the FDA Pharmacy Compounding Advisory Committee meeting on July 23–24, where six of the seven peptides under review received majority votes recommending their addition to the 503A bulks list.

Thank you to the organizers and to everyone who stopped by our table. We’re glad we could contribute a practical view of the testing layer that sits between supply and patients!

Follow us on X and LinkedIn and subscribe to our upcoming newsletter!